Leukemia & Lymphoma最新文献_第3页

Spontaneous regression of pharyngeal indeterminate dendritic cell tumor with KRAS and TP53 mutations. KRAS和TP53突变的咽部不确定树突状细胞肿瘤的自发消退。

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-09-13 DOI: 10.1080/10428194.2026.2731685

Yuta Tsunaga, Mitsuko Iguchi, Isao Yoshida, Kaori Hashimoto, Shohei Yoshida, Kensuke Kojima

引用次数: 0

Usefulness of 20-mm incisional random skin biopsy for diagnosis of intravascular large B-cell lymphoma: a single-center experience. 20mm切口随机皮肤活检诊断血管内大b细胞淋巴瘤的有效性：单中心经验。

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-09-12 DOI: 10.1080/10428194.2026.2731271

Kiyotaka Izumi, Ryuta Iwamoto, Mai Yano, Yuto Ueda, Kazuki Yoshioka, Bunta Kakihara, Kensuke Nakao, Tomoya Kitagawa, Katsuhiro Io

{"title":"Usefulness of 20-mm incisional random skin biopsy for diagnosis of intravascular large B-cell lymphoma: a single-center experience.","authors":"Kiyotaka Izumi, Ryuta Iwamoto, Mai Yano, Yuto Ueda, Kazuki Yoshioka, Bunta Kakihara, Kensuke Nakao, Tomoya Kitagawa, Katsuhiro Io","doi":"10.1080/10428194.2026.2731271","DOIUrl":"https://doi.org/10.1080/10428194.2026.2731271","url":null,"abstract":"Intravascular large B-cell lymphoma (IVLBCL) is a rare subtype of aggressive non-Hodgkin lymphoma characterized by the preferential proliferation of lymphoma cells within small vessels. Random skin biopsy (RSB) has been reported as a useful diagnostic tool for IVLBCL, although its sensitivity varies across studies. We retrospectively evaluated the efficacy and safety of the RSB method used at our institution. Between January 2022 and April 2026, 15 patients underwent RSB. Spindle-shaped incisions approximately 20 mm in length were made to obtain skin specimens containing subcutaneous fat. Six patients were diagnosed with IVLBCL by RSB. In most cases, IVLBCL cells were identified within vessels in the subcutaneous fat. Wider specimens contained a greater number of IVLBCL lesions. Hematoma formation occurred in one patient after RSB, and was successfully managed with supportive care. Our RSB method may facilitate the prompt diagnosis and treatment of patients suspected of having IVLBCL.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-7"},"PeriodicalIF":2.1,"publicationDate":"2026-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148956192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Optimized dosing of momelotinib in myelofibrosis through quantitative medicine: a clinical commentary. 通过定量医学优化莫米洛替尼在骨髓纤维化中的剂量：临床评论。

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-09-11 DOI: 10.1080/10428194.2026.2721768

Georgios Vlasakakis, Fernando Carreño, Meenakshi Srinivasan, Catherine E Ellis, Mahshid Azimi, Jasmine Sahni

引用次数: 0

Elevated expression of heme metabolism genes as a favorable biomarker in SF3B1-mutated myelodysplastic neoplasms. 血红素代谢基因在sf3b1突变的骨髓增生异常肿瘤中作为有利生物标志物的表达升高。

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-09-10 DOI: 10.1080/10428194.2026.2723848

Sophia Groh, Mona Schwendemann, Heiko Müller, Isolde Summerer, Torsten Haferlach, Wencke Walter, Alessandro Baldi, Manja Meggendorfer

引用次数: 0

Surface expression of ROR1 across lymphoma cell lines identifies models for preclinical evaluation of ROR1-targeting antibody-drug conjugates. ROR1在淋巴瘤细胞系中的表面表达为ROR1靶向抗体-药物偶联物的临床前评估确定了模型。

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-09-07 DOI: 10.1080/10428194.2026.2724722

Chiara Tarantelli, Elisa Civanelli, Filippo Spriano, Giorgia Risi, Luciano Cascione, Gunnar Kaufmann, Francesco Bertoni

引用次数: 0

Revisiting invasive fungal infections in acute lymphoblastic leukemia: a systematic review and meta-analysis. 急性淋巴细胞白血病侵袭性真菌感染的重访：一项系统回顾和荟萃分析。

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-09-06 DOI: 10.1080/10428194.2026.2724605

Christian M Farag, Ann Mercurio, Rejowana Rouf, Hannah Fried, Michelle Rudshteyn Korostin, Tianxiang Sheng, Douglas Tremblay, Risa Fuller, Hannah Levavi

{"title":"Revisiting invasive fungal infections in acute lymphoblastic leukemia: a systematic review and meta-analysis.","authors":"Christian M Farag, Ann Mercurio, Rejowana Rouf, Hannah Fried, Michelle Rudshteyn Korostin, Tianxiang Sheng, Douglas Tremblay, Risa Fuller, Hannah Levavi","doi":"10.1080/10428194.2026.2724605","DOIUrl":"https://doi.org/10.1080/10428194.2026.2724605","url":null,"abstract":"Invasive fungal infections (IFIs) cause substantial morbidity and mortality, yet optimal antifungal prophylaxis in adult acute lymphoblastic leukemia (ALL) remains uncertain given unclear incidence and drug interaction constraints. We performed a PRISMA 2020-compliant systematic review and meta-analysis (PROSPERO CRD420251048884) of PubMed, Embase, and Cochrane CENTRAL from inception through September 2025, including adults with ALL receiving antineoplastic therapy, excluding HSCT and pediatric cohorts. Primary outcome was IFI incidence per European Organization for Research and Treatment of Cancer and the Mycoses Study Group (EORTC/MSG) criteria; invasive aspergillosis (IA) was secondary. Of 1,789 records, 36 studies met eligibility; 23 contributed to meta-analyses. Pooled incidence of proven/probable IFI was 9% (95% CI 7-11%; N = 3,316), proven/probable/possible IFI 16% (12-21%; N = 806), and IA 5% (4-8%; N = 3,190). IFIs remain clinically significant in adult ALL, supporting risk-adapted prophylaxis during higher-risk treatment phases. Heterogeneity reflected differences in prophylaxis, treatment, and limited comparative data on strategies across studies.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-12"},"PeriodicalIF":2.1,"publicationDate":"2026-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148901075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting MCL-1 in cancer: promise, pitfalls, and the path forward. 靶向MCL-1治疗癌症：希望、陷阱和前进的道路。

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-09-06 DOI: 10.1080/10428194.2026.2723846

Aloke Sarkar, Natalia Timofeeva, Varsha Gandhi

引用次数: 0

MRD-guided induction-intensification with daratumumab-carfilzomib-based regimen followed by ASCT in patients with newly diagnosed multiple myeloma. 在新诊断的多发性骨髓瘤患者中，mrd引导下以daratumumab-carfilzomib为基础的诱导强化方案随后进行ASCT。

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-09-06 DOI: 10.1080/10428194.2026.2723847

Daizo Yokoyama, Daisuke Minakata, Shin-Ichiro Fujiwara, Seina Honda, Ryutaro Tominaga, Atsuto Noguchi, Shuka Furuki, Shunsuke Koyama, Rui Murahashi, Hirotomo Nakashima, Kazuki Hyodo, Shin-Ichiro Kawaguchi, Yumiko Toda, Kento Umino, Masuzu Ueda, Masahiro Ashizawa, Chihiro Yamamoto, Kaoru Hatano, Kazuya Sato, Ken Ohmine, Yoshinobu Kanda

{"title":"MRD-guided induction-intensification with daratumumab-carfilzomib-based regimen followed by ASCT in patients with newly diagnosed multiple myeloma.","authors":"Daizo Yokoyama, Daisuke Minakata, Shin-Ichiro Fujiwara, Seina Honda, Ryutaro Tominaga, Atsuto Noguchi, Shuka Furuki, Shunsuke Koyama, Rui Murahashi, Hirotomo Nakashima, Kazuki Hyodo, Shin-Ichiro Kawaguchi, Yumiko Toda, Kento Umino, Masuzu Ueda, Masahiro Ashizawa, Chihiro Yamamoto, Kaoru Hatano, Kazuya Sato, Ken Ohmine, Yoshinobu Kanda","doi":"10.1080/10428194.2026.2723847","DOIUrl":"https://doi.org/10.1080/10428194.2026.2723847","url":null,"abstract":"This single-institution retrospective study evaluated a measurable residual disease (MRD)-guided induction intensification strategy in transplant-eligible patients with newly diagnosed multiple myeloma treated in the anti-CD38 antibody era. Sixty patients undergoing autologous stem cell transplantation (ASCT) between 2020 and 2025 were included. Most received bortezomib, lenalidomide, and dexamethasone as initial therapy. Patients with persistent MRD by multiparameter flow cytometry underwent treatment intensification, commonly with daratumumab, carfilzomib, and dexamethasone before ASCT. Among 52 evaluable patients, 35 (67.3%) achieved MRD negativity before ASCT, and 30 of 32 (93.8%) were MRD-negative after ASCT. Stem cell mobilization and engraftment were successful. After median follow-up of 28.5 months, 2-year progression-free and overall survival were 87.3% and 98.0%. R-ISS stage III and extramedullary disease were associated with inferior progression-free survival. High-risk cytogenetics showed poorer outcomes. This MRD-adapted strategy was feasible, achieved deep responses, and preserved mobilization, but high-risk disease remained prone to relapse, supporting post-transplant intensification.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-13"},"PeriodicalIF":2.1,"publicationDate":"2026-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148901059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Response to Borrás-Blasco et al. regarding "Real-world venetoclax dosing patterns and treatment persistence in patients with acute myeloid leukemia: a community pharmacy database study in Japan". 对Borrás-Blasco等人关于“急性髓性白血病患者的真实世界venetoclax给药模式和治疗持久性：日本社区药房数据库研究”的回应。

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-09-06 DOI: 10.1080/10428194.2026.2724604

Yuki Goshima, Tomoya Saika, Yuki Kado, Michiko Yamazaki, Tohru Takebe, Shunsuke Yui

引用次数: 0

Targeted RNA sequencing supports risk stratification and treatment decision-making in adolescents and young adult and adult patients with acute lymphoblastic leukemia: a UK single-center experience. 靶向RNA测序支持青少年、青年和成年急性淋巴细胞白血病患者的风险分层和治疗决策：英国单中心经验

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-09-06 DOI: 10.1080/10428194.2026.2726608

Athanasia Papadaki, Robert Baker, Elisabeth Nacheva, Jenny O'Nions, Andrew J Wilson, Rajeev Gupta, Ke Xu

引用次数: 0